(1) The Awarded Shares (or a portion of the shares) will only be earned based upon the achievement of certain significant milestones leading to the
commercialization of CEL-SCI’s Multikine technology or significant increases in the market price of CEL-SCI’s common shares.
Upon the achievement of the following performance goals, a percentage of the Awarded Shares will be earned by the Grantees and will no longer be
subject to being forfeited to CEL-SCI.
i. Upon either (a) the enrollment of 350 patients in the Phase 3 head and neck cancer study or (b) the closing price of a share of CEL-SCI’s common
stock on the primary exchange on which such common stock is then traded exceeds $87.50 for ten consecutive trading days, each Grantee shall
earn 25% of the Awarded Shares.
ii. Upon either (a) the full enrollment of patients in the Phase 3 head and neck cancer study or (b) the start of a pivotal clinical trial for Multikine (the
"Proprietary Technology") in a disease indication other than head and neck cancer or (c) the closing price of a share of CEL-SCI’s common stock
on the primary exchange on which the common stock is then traded exceeds $150.00 for ten consecutive trading days, each Grantee will earn
50% of the Awarded Shares, less any of the Awarded Shares previously earned.
iii. Upon either (a) the end of the Phase 3 head and neck cancer study or any other pivotal study involving CEL-SCI’s proprietary technology, or (b)
the closing price of a share of CEL-SCI’s common stock on the primary exchange on which the common stock is then traded exceeds $225.00 for
ten consecutive trading days, each Grantee will earn 75% of the Awarded Shares, less any of the Awarded Shares previously earned.
12
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
iv. Upon either (a) the filing of the first marketing application for any pharmaceutical based upon CEL-SCI’s proprietary technology in the USA,
Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) the closing price of a share of CEL-SCI’s common stock on the primary
exchange on which the common stock is then traded exceeds $300.00 for ten consecutive trading days, each Grantee will earn 100% of the
Awarded Shares, less any of the Awarded Shares previously earned.
Seems like it says further down they would need to file a prospectus to sell their shares?
